Pharmaceutical firm Cytogen and radiopharmaceutical manufacturer DraxImage said that production and sales of the palladium version of their BrachySeed prostate cancer brachytherapy implants have been halted for an unspecified period of time. The firms did not provide additional details, other than to say that they are discussing ways to resolve issues surrounding palladium BrachySeed production and sales.
Princeton, NJ-based Cytogen launched BrachySeed Pd-103 commercially in May 2002. The firm had signed a 10-year agreement with Mississauga, Ontario-based DraxImage in December 2000 to market and distribute BrachySeed iodine and palladium implants in the U.S. Production and sales of the iodine-125 version of BrachySeed are continuing unchanged, according to the vendors.
By AuntMinnie.com staff writersJanuary 17, 2003
Related Reading
Draxis Health starts phase I trials, January 9, 2003
Cytogen regains rights to PMSA therapy, January 3, 2003
Cytogen gets new CEO, December 19, 2002
Draxis Health’s Q3 revenues climb 10%, November 14, 2002
Draxis gets NRC approval for BrachySeed Pd-103, November 13, 2001
Copyright © 2003 AuntMinnie.com
